RUMOSPAS-20
MRP: 2,201
Packaging: 10x10
Pack Type: tablet
Composition:
Leflunomide 20mg
Indication:
for the treatment of active rheumatoid arthritis and psoriatic arthritis to reduce joint inflammation, pain, and prevent disease progression.
Description:
Leflunomide 20 mg is an immunomodulatory and anti-inflammatory drug primarily used in the management of rheumatoid arthritis and psoriatic arthritis. It works by inhibiting the synthesis of pyrimidines, leading to a reduction in the proliferation of activated lymphocytes—key contributors to autoimmune inflammation.
This drug helps relieve joint pain, swelling, and stiffness and slows the progression of joint damage. It is often used when patients cannot tolerate or do not respond adequately to other Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Tags:
- Reduces joint inflammation, pain, and swelling
- Slows the progression of rheumatoid and psoriatic arthritis
- Improves mobility and quality of life
- Suitable as a monotherapy or in combination with other DMARDs
- Long-acting, once-daily dosing for convenience
Usage Information
Dosage
Typical adult dose: 20 mg once daily (with or without food) In some cases, a loading dose (100 mg/day for 3 days) may be used, then continued with 20 mg/day Take exactly as prescribed by a rheumatologist or physician Regular liver function and blood count monitoring is essential during treatment
Side Effects
Common: Diarrhea, nausea, elevated liver enzymes, hair thinning Less common: Rash, headache, dizziness, respiratory issues Serious (rare): Hepatotoxicity, bone marrow suppression, interstitial lung disease
Contraindications
Pregnancy (Category X) – strictly contraindicated; may cause fetal harm Severe liver disease or active liver dysfunction History of serious infections or immunodeficiency Known hypersensitivity to leflunomide or its metabolites Avoid in breastfeeding women